Rochester, United States
Research view
Melanoma: who works on it
Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
Find fellow researchers
One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.
- All targets
- PD-1 54
- BRAF 18
- PD-L1 21
- MEK 7
- TP53 0
- CTLA-4 10
- MAPK 2
- NRAS 8
- STING 0
- STAT3 0
- PRAME 3
- AKT 0
- PI3K 0
- BAP1 2
- VEGF 4
- mTOR 0
- ERK 0
- LAG-3 2
- RAS 2
- CTNNB1 0
- CD40 0
- CDKN2A 3
- TNF 0
- YAP 0
- PTEN 1
- JAK 0
- KIT 3
- KRAS 1
- JNK 0
- PPAR 0
- TIGIT 0
- ALK 0
- B7-H3 3
- BCL-2 0
- EZH2 0
- HIF-1 0
- IL-15 1
- NF1 2
- NLRP3 0
- NRF2 0
- AMPK 0
- HSP90 0
- CD47 0
- MYC 0
- PKM2 0
- AXL 1
- COX-2 0
- EGFR 0
- GPX4 0
- MET 1
- HDAC 1
- IDH 1
- IL-17 1
- MMP-9 0
- CDK4/6 0
- CXCR4 0
- FGFR 0
- HER2 3
- IGF1R 0
- PSMA 3
EU-13 is a filter, not a ranking: it only narrows the list.
University of Pennsylvania · Philadelphia, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · Proc Natl Acad Sci U S A, Dec 2025Dual-targeted ping-pong CAR T cells: Leveraging peripheral expansion to improve solid tumor immunotherapy.
Coral Gables, United States
Brigham and Women's Hospital · Boston, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Latest publication · Mil Med Res, Nov 2025Diverging global incidence trends of early-onset cancers: comparisons with incidence trends of later-onset cancers and mortality trends of early-onset cancers.
New York, United States
San Diego, United States
New York, United States
Toronto, Canada
Philadelphia, United States
Melbourne, Australia
Seattle, United States
New York, United States
New York, United States
Chicago, United States
Birmingham, United States
Irvine, United States
Buffalo, United States
17 of 17+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.
Who stopped a trial, and why
Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.
Terminated
“Trial terminated due to a business decision, not based on any safety concerns.”Registry text, quoted unchanged. Source
Terminated
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
“Limited resources and strategic priorities”Registry text, quoted unchanged. Source
Suspended
“Sponsor decision”Registry text, quoted unchanged. Source
Terminated
“Sponsor decision”Registry text, quoted unchanged. Source
Trials that share participant data
Trials whose registry record says individual participant data (IPD) will be shared.
Search by method
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
- Single-Cell Analysis 51
- Organoids 8
- Mendelian Randomization Analysis 12
- CRISPR-Cas Systems 22
- Gene Expression Profiling 116
- Sequence Analysis, RNA 9
- Whole Genome Sequencing 6
- Exome Sequencing 7
- Proteomics 47
- Metabolomics 20
- Mass Spectrometry 10
- Flow Cytometry 65
- Immunohistochemistry 106
- Liquid Biopsy 12
- Circulating Tumor DNA 37
- Xenograft Model Antitumor Assays 121
- Positron-Emission Tomography 31
- Magnetic Resonance Imaging 57
- Machine Learning 49
- Deep Learning 44
- Cohort Studies 78
- Genome-Wide Association Study 22
Imaging Manifestations and Clinical Analysis of 12 Cases of Anorectal Malignant Melanoma.
Non-invasive Imaging Modalities for Breslow Thickness Estimation in Melanoma: A Scoping Review.
Systemic surveillance for uveal melanoma: Approach to optimization.
Radiomics for risk stratification in brain metastases: potential in melanoma brain metastases.
Paste an abstract
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed. Machine-matched links are labelled.